Docetaxel metabolism is not altered by imatinib: Findings from an early phase study in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 127, Issue 1, 2011, Pages 153-162

  Connolly, Roisin M ^a   Rudek, Michelle A ^a   Garrett Mayer, Elizabeth ^a,d   Jeter, Stacie C ^a   Donehower, Michele G ^a   Wright, Laurie A ^a   Zhao, Ming ^a   Fetting, John H ^a   Emens, Leisha A ^a   Stearns, Vered ^a   Davidson, Nancy E ^a,b   Baker, Sharyn D ^a,c   Wolff, Antonio C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; CYP3A4 inhibitor; Docetaxel; Imatinib; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 3A4; DOCETAXEL; ERYTHROMYCIN; IMATINIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BREATH ANALYSIS; CLINICAL ARTICLE; DEHYDRATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; EPIPHORA; FACE EDEMA; FATIGUE; FEMALE; FLATULENCE; FLUSHING; HOT FLUSH; HUMAN; HYPOKALEMIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTATIC BREAST CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAIL DISEASE; NAUSEA; NEUTROPENIA; NOSE DISEASE; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STEADY STATE; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TAXOIDS; TREATMENT OUTCOME;

EID: 79954917723     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1413-6     Document Type: Article

References (47)

1. F Lavelle MC Bissery C Combeau JF Riou P Vrignaud S Andre 1995 Preclinical evaluation of docetaxel (Taxotere) Semin Oncol 22 3 16 1:CAS:528:DyaK2MXmt1Onu7c%3D
2. M Martin T Pienkowski J Mackey M Pawlicki JP Guastalla C Weaver E Tomiak T Al-Tweigeri L Chap E Juhos R Guevin A Howell T Fornander J Hainsworth R Coleman J Vinholes M Modiano T Pinter SC Tang B Colwell C Prady L Provencher D Walde A Rodriguez-Lescure J Hugh C Loret M Rupin S Blitz P Jacobs M Murawsky A Riva C Vogel 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313 10.1056/NEJMoa043681 15930421 10.1056/NEJMoa043681 1:CAS:528:DC%2BD2MXksl2lt7c%3D (Pubitemid 40740554)
3. S Jones FA Holmes J O'Shaughnessy JL Blum SJ Vukelja KJ McIntyre JE Pippen JH Bordelon RL Kirby J Sandbach WJ Hyman DA Richards RG Mennel KA Boehm WG Meyer L Asmar D Mackey S Riedel H Muss MA Savin 2009 Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 J Clin Oncol 27 1177 1183 10.1200/JCO.2008.18.4028 19204201 10.1200/JCO.2008.18.4028 1:CAS:528:DC%2BD1MXktFKhs7c%3D
4. JM Nabholtz HJ Senn WR Bezwoda D Melnychuk L Deschenes J Douma TA Vandenberg B Rapoport R Rosso V Trillet-Lenoir J Drbal A Molino JW Nortier DJ Richel T Nagykalnai P Siedlecki N Wilking JY Genot PS Hupperets F Pannuti D Skarlos EM Tomiak M Murawsky M Alakl M Aapro, et al. 1999 Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group J Clin Oncol 17 1413 1424 10334526 1:CAS:528:DyaK1MXjsF2msrc%3D (Pubitemid 29220847)
5. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory. Accessed online 15 Jan 2011
6. M Martin MA Segui A Anton A Ruiz M Ramos E Adrover I Aranda A Rodriguez-Lescure R Grosse L Calvo A Barnadas D Isla P Martinez del Prado M Ruiz Borrego J Zaluski A Arcusa M Munoz JM Lopez Vega JR Mel B Munarriz C Llorca C Jara E Alba J Florian J Li JA Lopez Garcia-Asenjo A Saez MJ Rios S Almenar G Peiro A Lluch 2010 Adjuvant docetaxel for high-risk, node-negative breast cancer N Engl J Med 363 2200 2210 10.1056/NEJMoa0910320 21121833 10.1056/NEJMoa0910320 1:CAS:528:DC%2BC3cXhsFWqsb7N
7. AE Roussidis TN Mitropoulou AD Theocharis C Kiamouris S Papadopoulos D Kletsas NK Karamanos 2004 STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells Anticancer Res 24 1445 1447 15274308 1:CAS:528:DC%2BD2cXmsV2jsLw%3D (Pubitemid 38954662)
8. JT Sims S Ganguly LS Fiore CJ Holler ES Park R Plattner 2009 STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner Biochem Pharmacol 78 249 260 S0006-2952(09)00292- 510.1016/j.bcp.2009.04.007 19427998 10.1016/j.bcp.2009.04.007 1:CAS:528:DC%2BD1MXms1Wgs7s%3D
9. P Mathew PF Thall D Jones C Perez C Bucana P Troncoso SJ Kim IJ Fidler C Logothetis 2004 Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer J Clin Oncol 22 3323 3329 10.1200/JCO.2004.10.11622/16/3323 15310776 10.1200/JCO.2004.10.116 1:CAS:528:DC%2BD2cXpsVGrsb0%3D (Pubitemid 41103689)
10. DS Krause RA Van Etten 2005 Tyrosine kinases as targets for cancer therapy N Engl J Med 353 172 187 353/2/17210.1056/NEJMra044389 16014887 10.1056/NEJMra044389 1:CAS:528:DC%2BD2MXmtFClsbs%3D (Pubitemid 41058349)
11. MW Karaman S Herrgard DK Treiber P Gallant CE Atteridge BT Campbell KW Chan P Ciceri MI Davis PT Edeen R Faraoni M Floyd JP Hunt DJ Lockhart ZV Milanov MJ Morrison G Pallares HK Patel S Pritchard LM Wodicka PP Zarrinkar 2008 A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 127 132 10.1038/nbt1358 18183025 10.1038/nbt1358 1:CAS:528:DC%2BD1cXisFGlsQ%3D%3D
12. B Bhardwaj J Klassen N Cossette E Sterns A Tuck R Deeley S Sengupta B Elliott 1996 Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma Clin Cancer Res 2 773 782 9816230 1:CAS:528:DyaK28Xis1Wlurc%3D (Pubitemid 26135343)
13. K Pietras K Rubin T Sjoblom E Buchdunger M Sjoquist CH Heldin A Ostman 2002 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res 62 5476 5484 12359756 1:CAS:528: DC%2BD38Xnsl2lsL4%3D
14. K Pietras A Ostman M Sjoquist E Buchdunger RK Reed CH Heldin K Rubin 2001 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 61 2929 2934 11306470 1:CAS:528:DC%2BD3MXivFGqsro%3D (Pubitemid 32691937)
15. C Sotiriou SY Neo LM McShane EL Korn PM Long A Jazaeri P Martiat SB Fox AL Harris ET Liu 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 10393 10398 10.1073/pnas.1732912100 12917485 10.1073/pnas.1732912100 1:CAS:528:DC%2BD3sXntFynsrk%3D (Pubitemid 37071889)
16. FK Engels AJ Ten Tije SD Baker CK Lee WJ Loos AG Vulto J Verweij A Sparreboom 2004 Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel Clin Pharmacol Ther 75 448 454 10.1016/j.clpt.2004.01.001 15116057 10.1016/j.clpt.2004.01.001 1:CAS:528:DC%2BD2cXjs1Cjtbo%3D (Pubitemid 38534565)
17. R Bruno D Hille A Riva N Vivier WW ten Bokkel Huinnink AT van Oosterom SB Kaye J Verweij FV Fossella V Valero JR Rigas AD Seidman B Chevallier P Fumoleau HA Burris PM Ravdin LB Sheiner 1998 Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 16 187 196 9440742 1:CAS:528:DyaK1cXmsVejtg%3D%3D (Pubitemid 28041598)
18. H Gurney M Wong RL Balleine LP Rivory AJ McLachlan JM Hoskins N Wilcken CL Clarke GJ Mann M Collins SE Delforce K Lynch H Schran 2007 Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype Clin Pharmacol Ther 82 33 40 10.1038/sj.clpt.6100201 17495881 10.1038/sj.clpt.6100201 1:CAS:528: DC%2BD2sXotVGju78%3D (Pubitemid 46944197)
19. http://products.sanofi-aventis.us/Taxotere/taxotere.html#S15. Accessed online 15 Jan 2011
20. SD Baker M Zhao CK Lee J Verweij Y Zabelina JR Brahmer AC Wolff A Sparreboom MA Carducci 2004 Comparative pharmacokinetics of weekly and every-three-weeks docetaxel Clin Cancer Res 10 1976 1983 15041715 10.1158/1078-0432.CCR-0842-03 1:CAS:528:DC%2BD2cXisVGlu7w%3D (Pubitemid 38375556)
21. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
22. SD Baker RH van Schaik LP Rivory AJ Ten Tije K Dinh WJ Graveland PW Schenk KA Charles SJ Clarke MA Carducci WP McGuire F Dawkins H Gelderblom J Verweij A Sparreboom 2004 Factors affecting cytochrome P-450 3A activity in cancer patients Clin Cancer Res 10 8341 8350 10/24/834110.1158/1078-0432.CCR-04- 1371 15623611 10.1158/1078-0432.CCR-04-1371 1:CAS:528:DC%2BD2cXhtFGjs7%2FM (Pubitemid 40053395)
23. SD Baker M Zhao P He MA Carducci J Verweij A Sparreboom 2004 Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry Anal Biochem 324 276 284 14690692 10.1016/j.ab.2003.09.038 1:CAS:528:DC%2BD3sXhtVSjurrE (Pubitemid 38019018)
24. NP van Erp H Gelderblom MO Karlsson J Li M Zhao J Ouwerkerk JW Nortier HJ Guchelaar SD Baker A Sparreboom 2007 Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib Clin Cancer Res 13 7394 7400 10.1158/1078-0432.CCR-07-0346 18094422 10.1158/1078-0432.CCR-07-0346
25. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York, NY, pp 409-417
26. B Peng P Lloyd H Schran 2005 Clinical pharmacokinetics of imatinib Clin Pharmacokinet 44 879 894 16122278 10.2165/00003088-200544090-00001 1:CAS:528:DC%2BD2MXhtFSktbzF (Pubitemid 41252840)
27. RA Larson BJ Druker F Guilhot SG O'Brien GJ Riviere T Krahnke I Gathmann Y Wang 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 4028 10.1182/blood-2007-10-116475 18256322 10.1182/blood-2007-10-116475 1:CAS:528:DC%2BD1cXkvFeisrg%3D
28. GD Demetri Y Wang E Wehrle A Racine Z Nikolova CD Blanke H Joensuu M von Mehren 2009 Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors J Clin Oncol 27 3141 3147 JCO.2008.20.481810.1200/JCO.2008.20.4818 19451435 10.1200/JCO.2008.20.4818 1:CAS:528:DC%2BD1MXhtFWitb3K
29. SG O'Brien P Meinhardt E Bond J Beck B Peng C Dutreix G Mehring S Milosavljev C Huber R Capdeville T Fischer 2003 Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia Br J Cancer 89 1855 1859 10.1038/sj.bjc.6601152 14612892 10.1038/sj.bjc.6601152 (Pubitemid 37533259)
30. AC Hooker AJ Ten Tije MA Carducci J Weber E Garrett-Mayer H Gelderblom WP McGuire J Verweij MO Karlsson SD Baker 2008 Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements Clin Pharmacol Ther 84 111 118 10.1038/sj.clpt.6100476 18183036 10.1038/sj.clpt.6100476 1:CAS:528: DC%2BD1cXnt1KqsLo%3D (Pubitemid 351861492)
31. J Hirth PB Watkins M Strawderman A Schott R Bruno LH Baker 2000 The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance Clin Cancer Res 6 1255 1258 10778948 1:CAS:528:DC%2BD3cXjtVOqtrw%3D (Pubitemid 30226205)
32. KA Slaviero SJ Clarke AJ McLachlan EY Blair LP Rivory 2004 Population pharmacokinetics of weekly docetaxel in patients with advanced cancer Br J Clin Pharmacol 57 44 53 1956 14678339 10.1046/j.1365-2125.2003.01956.x 1:CAS:528:DC%2BD2cXotlOjug%3D%3D (Pubitemid 38067949)
33. SD Baker J Verweij GA Cusatis RH van Schaik S Marsh SJ Orwick RM Franke S Hu EG Schuetz V Lamba WA Messersmith AC Wolff MA Carducci A Sparreboom 2009 Pharmacogenetic pathway analysis of docetaxel elimination Clin Pharmacol Ther 85 155 163 10.1038/clpt.2008.95 18509327 10.1038/clpt.2008.95 1:CAS:528: DC%2BD1MXmt1Cquw%3D%3D
34. RM Franke SD Baker RH Mathijssen EG Schuetz A Sparreboom 2008 Influence of solute carriers on the pharmacokinetics of CYP3A4 probes Clin Pharmacol Ther 84 704 709 10.1038/clpt.2008.94 18509328 10.1038/clpt.2008.94 1:CAS:528:DC%2BD1cXhtlOjtr%2FF
35. S Hu RM Franke KK Filipski C Hu SJ Orwick EA de Bruijn H Burger SD Baker A Sparreboom 2008 Interaction of imatinib with human organic ion carriers Clin Cancer Res 14 3141 3148 10.1158/1078-0432.CCR-07-4913 18483382 10.1158/1078-0432.CCR-07-4913 1:CAS:528:DC%2BD1cXmtVCmuro%3D
36. RM Franke A Sparreboom 2008 Inhibition of imatinib transport by uremic toxins during renal failure J Clin Oncol 26 4226 4227 10.1200/JCO.2008.18.4390 18757345 10.1200/JCO.2008.18.4390 author reply 4227-4228
37. LA Frassetto S Poon C Tsourounis C Valera LZ Benet 2007 Effects of uptake and efflux transporter inhibition on erythromycin breath test results Clin Pharmacol Ther 81 828 832 10.1038/sj.clpt.6100148 17361125 10.1038/sj.clpt. 6100148 1:CAS:528:DC%2BD2sXmsF2iurc%3D (Pubitemid 46788293)
38. VD Schmith JF Foss 2008 Effects of inflammation on pharmacokinetics/ pharmacodynamics: increasing recognition of its contribution to variability in response Clin Pharmacol Ther 83 809 811 10.1038/clpt.2008.62 18488052 10.1038/clpt.2008.62 1:CAS:528:DC%2BD1cXlvFOrtbk%3D (Pubitemid 351704932)
39. AD Seidman D Berry C Cirrincione L Harris H Muss PK Marcom G Gipson H Burstein D Lake CL Shapiro P Ungaro L Norton E Winer C Hudis 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649 10.1200/JCO.2007.11.6699 18375893 10.1200/JCO.2007.11.6699 1:CAS:528: DC%2BD1cXltlWhsr0%3D
40. JA Sparano M Wang S Martino V Jones EA Perez T Saphner AC Wolff GW Sledge Jr WC Wood NE Davidson 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 10.1056/NEJMoa0707056 18420499 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D (Pubitemid 351549913)
41. H Uehara SJ Kim T Karashima DL Shepherd D Fan R Tsan JJ Killion C Logothetis P Mathew IJ Fidler 2003 Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases J Natl Cancer Inst 95 458 470 12644539 10.1093/jnci/95.6.458 1:CAS:528:DC%2BD3sXisFCqs7w%3D (Pubitemid 36432420)
42. P Mathew PF Thall CD Bucana WK Oh MJ Morris DM Jones MM Johnson S Wen LC Pagliaro NM Tannir SM Tu AA Meluch L Smith L Cohen SJ Kim P Troncoso IJ Fidler CJ Logothetis 2007 Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases Clin Cancer Res 13 5816 5824 10.1158/1078-0432.CCR-07-1269 17908974 10.1158/1078-0432.CCR-07-1269 1:CAS:528:DC%2BD2sXhtFSntLrK (Pubitemid 47583906)
43. P Mathew LL Pisters CG Wood JN Papadopoulos DL Williams PF Thall S Wen E Horne CJ Oborn R Langley IJ Fidler CA Pettaway 2009 Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer J Urol 181 81 87 10.1016/j.juro.2008.09.006 19012911 10.1016/j.juro.2008.09.006 1:CAS:528:DC%2BD1MXht1entr4%3D discussion 87
44. M Cristofanilli P Morandi S Krishnamurthy JM Reuben BN Lee D Francis DJ Booser MC Green BK Arun L Pusztai A Lopez R Islam V Valero GN Hortobagyi 2008 Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations Ann Oncol 19 1713 1719 10.1093/annonc/mdn352 18515258 10.1093/annonc/mdn352 1:STN:280: DC%2BD1cnhslKnsg%3D%3D
45. S Modi AD Seidman M Dickler M Moasser G D'Andrea ME Moynahan J Menell KS Panageas LK Tan L Norton CA Hudis 2005 A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer Breast Cancer Res Treat 90 157 163 10.1007/s10549-004-3974-0 15803362 10.1007/s10549-004-3974-0 1:CAS:528:DC%2BD2MXivVKhs7o%3D
46. HK Chew WE Barlow K Albain D Lew A Gown DF Hayes J Gralow GN Hortobagyi R Livingston 2008 A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338 Clin Breast Cancer 8 511 515 62183P0858797V3N10.3816/CBC.2008.n.062 19073506 10.3816/CBC.2008.n. 062 1:CAS:528:DC%2BD1MXhtVGiu7s%3D
47. DA Yardley HA Burris III T Markus DR Spigel FA Greco M Mainwaring DM Waterhouse CD Webb JD Hainsworth 2009 Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer Clin Breast Cancer 9 237 242 10.3816/CBC.2009.n.040 19933079 10.3816/CBC.2009.n.040 1:CAS:528:DC%2BD1MXhsF2iu73P